Did outcry on social media lead to Mylan’s generic EpiPen?

Name: Did outcry on social media lead to Mylan’s generic EpiPen?
Uploaded: 2016-08-29T23:16:30Z
Duration: P461S

Clip: 08/29/2016 | 7m 41s

After news broke that the price of EpiPen injectors has skyrocketed, the allergy medicine’s maker, Mylan, announced its intention to offer a generic version of the product, to be sold at half the market price of the original. The New York Times’ Andrew Pollack and the University of Minnesota's Stephen Schondelmeyer talk with Gwen Ifill about the role public outcry played in the company's decision.

Aired: 08/29/16

Rating: NR

Problems Playing Video? | Closed Captioning

Major corporate funding for the PBS NewsHour is provided by BDO, BNSF, Consumer Cellular, American Cruise Lines, and Raymond James. Funding for the PBS NewsHour Weekend is provided by Consumer …

Major corporate funding for the PBS NewsHour is provided by BDO, BNSF, Consumer Cellular, American Cruise Lines, and Raymond James. Funding for the PBS NewsHour Weekend is provided by Consumer Cellular and American Cruise Lines. For a complete list of funders for the PBS NewsHour and PBS NewsHour weekend, click here.

Support provided by:

Did outcry on social media lead to Mylan’s generic EpiPen?

More News and Public Affairs Shows